液体活检在胶质瘤中的应用及展望

胶质瘤是一种最常见的原发性颅内肿瘤，由于其早期诊断困难、解剖位置复杂及复发率高，导致其预后极差，使之成为致死性最高的恶性肿瘤之一。近几年来，随着二代测序技术的发展，液体活检以可重复性和微创为特点在胶质瘤的早期发现、耐药监测、靶点检测及预后预测中表现出了良好的应用前景。然而，液体活检在胶质瘤患者临床应用中仍面临着一系列的挑战，本文综述液体活检及其生物标志物在胶质瘤中的研究进展及其临床应用。

Glioma is one of the most common primary intracranial tumors. Due to difficulty of early diagnosis, complicated anatomical location and high recurrence rate, it has a very poor prognosis, making it one of the most fatal malignant tumors. In recent years, with the development of second-generation sequencing technology, liquid biopsy characterized by reproducible and minimally invasive methods has shown promising applications in the early detection, drug resistance monitoring, target detection and prognostic prediction of glioma. However, liquid biopsy still faces several columns of challenges in the clinical application of glioma patients. Therefore, this paper will explore the progress of liquid biopsy and its biomarkers and its clinical application in glioma.